Novo Nordisk A/S
Hims & Hers brings former Amazon executive into C-suite
Bringing nearly 20 years of global experience at Amazon, Nader Kabbani is joining the executive leadership team to help the company further innovate on the delivery of affordable, seamless personalized care in the U.S. and globally. Courtesy: Hims & Hers Hims & Hers Health on Monday announced Nader Kabbani, a former Amazon executive who helped […]
Read More
Inside the deal: Roche and Zealand Pharma’s $5.3 billion obesity drug gambit
A view of the sign and logo of the Roche Holding AG headquarters on April 11, 2025 in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma’s “next generation” […]
Read More
UK stocks choppy amid best run in 8 years; Novo Nordisk jumps 5%
The morning after US President Trump’s announcement of European and worldwide trade tariffs, which included a 10% levy for imported goods from the UK, shoppers spend on Oxford Street beneath union jack flags in London’s West End, on 3rd April 2025, in London, England. Richard Baker | In Pictures | Getty Images LONDON — The […]
Read More
CVS to boost access to Novo Nordisk’s weight loss treatment Wegovy for patients on its drug plans
The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images CVS Health on Thursday said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its […]
Read More
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
Eli Lilly on Thursday reported first-quarter revenue and earnings that topped estimates as demand for its weight loss and diabetes drugs soared, but lowered its full-year profit guidance due to charges related to a recent cancer treatment deal. The pharmaceutical giant now expects its adjusted fiscal 2025 earnings to come in between $20.78 and $22.28 […]
Read More
Stocks making the biggest moves midday: Spotify, Regeneron, Hims & Hers, Pfizer and more
Check out the companies making headlines in midday trading: Spotify — Shares of the music streaming company lost 3.8% on the back of disappointing results. Spotify reported first-quarter operating income of 509 million euros, while analysts polled by FactSet expected 519.9 million euros. Spotify’s revenue of 4.2 billion euros was in line with estimates, while […]
Read More
Novo Nordisk opens weight loss drug Wegovy to telehealth; Hims & Hers shares rocket 30%
The “Wegovy” brand slimming syringe is sold in the Achat pharmacy in Mitte. The “Wegovy” slimming syringe has been available in Germany for a year. Jens Kalaene | Picture Alliance | Getty Images Novo Nordisk on Tuesday said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and […]
Read More
Novo Nordisk scores major legal win that bars many compounded versions of Wegovy, Ozempic
Flags with the logos of Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy are pictures while the company presents the annual report at Novo Nordisk in Bagsvaerd, Denmark, on February 5, 2025. Mads Claus Rasmussen | Afp | Getty Images Novo Nordisk scored a huge legal victory that […]
Read More
Healthy Returns: Trump seeks to change Medicare drug price negotiations in a win for pharma
U.S. President Donald Trump speaks to the media during the annual White House Easter Egg Roll, on the South Lawn of the White House in Washington, D.C., U.S., April 21, 2025. Leah Millis | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to […]
Read More
5 European stocks to watch this earnings season as Trump’s tariffs hit
Investors are entering 2025’s first-quarter earnings season with a huge cloud of uncertainty hanging over them — thanks primarily to U.S. President Donald Trump’s tariffs. The scale of duties announced in April, along with the volatility injected by subsequent updates and reversals in policy, have so far exceeded even the most bearish forecasts. Negotiators from […]
Read More